<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although some studies have validated the 2001 World Health Organization (WHO) classification of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), including the importance of multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, others have suggested that multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> correlates with unfavorable cytogenetics but has no independent impact on prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>In 2008, the revised WHO classification has expanded this category into "<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes" (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC) </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the clinical, pathologic, cytogenetic, and molecular features of 100 AML patients using the 2008 WHO criteria </plain></SENT>
<SENT sid="3" pm="."><plain>Patients underwent genetic screening for NPM1, FLT3-ITD, FLT3-D835, and CEBPA mutations </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, not otherwise specified, patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC were significantly older (P= .014), presented with a lower <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (P= .044), more frequently expressed CD14 (P= .048), and exhibited a decreased frequency of CEBPA mutations (P= .001) </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis indicated that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC had a significantly worse overall survival, progression-free survival, and complete response compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-not otherwise specified (<z:hpo ids='HP_0000001'>all</z:hpo> P&lt; .001) </plain></SENT>
<SENT sid="6" pm="."><plain>These data support the clinical, morphologic, and cytogenetic criteria for this 2008 WHO <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> category </plain></SENT>
</text></document>